In vitro and in vivo activities of formycin B against Trypanosoma cruzi.
The inosine analog formycin B was examined for in vitro and in vivo activities against Trypanosoma cruzi. concentration of formycin B as low as 0.1 microgram/ml markedly inhibited intracellular multiplication of T. cruzi strains both in macrophages and in L929 cells. Mice infected with 10(5) blood form trypomastigotes of the highly virulent strain Y of T. cruzi were completely protected against death by treatment with 11.8 or 5.9 mg of formycin B per kg administered intraperitoneally each day for 19 days. Four different strains of T. cruzi were used, and each was susceptible to formycin B administered either intraperitoneally or orally. Parasitological cure, however, was not achieved with any of the treatments used, including prolonged treatment for up to 10 weeks. Formycin B has a remarkable capacity for inhibiting the in vitro intracellular replication of T. cruzi and protecting mice against death due to the acute infection with the organism. It does not appear, however, to be able to completely eliminate T. cruzi from infected mice.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D014355:Chagas Disease / Q000097:blood / Q000188:drug therapy / Q000469:parasitology; D005260:Female; D005573:Formycins / Q000494:pharmacology* / Q000627:therapeutic use; D051379:Mice; D010587:Phagocytosis / Q000187:drug effects; D013997:Time Factors; D014349:Trypanosoma cruzi / Q000187:drug effects*
D000903:Antibiotics, Antineoplastic; D005573:Formycins; C034561:formycin B